ClinicalTrials.govpublic full text
Levocarnitine for Reducing ESA Requirements in Hemodialysis Patients With Renal Anemia
anemia, kidney failure, end-stage renal disease, renal dialysis, levocarnitine, l-carnitine, erythropoiesis-stimulating agents, erythropoietin responsiveness index, hematocrit, interventional, phase4
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 844876
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.